Liver Is the Site of Splanchnic Cortisol Production in Obese Nondiabetic Humans

OBJECTIVE—To determine the contribution of liver and viscera to splanchnic cortisol production in humans. RESEARCH DESIGN AND METHODS—D4 cortisol was infused intravenously; arterial, portal venous, and hepatic venous blood was sampled; and liver and visceral fat were biopsied in subjects undergoing bariatric surgery. RESULTS—Ratios of arterial and portal vein D4 cortisol/cortisoltotal (0.06 ± 0.01 vs. 0.06 ± 0.01) and D4 cortisol/D3 cortisol (1.80 ± 0.14 vs. 1.84 ± 0.14) did not differ, indicating that no visceral cortisol production or conversion of D4 cortisol to D3 cortisol via 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) occurred. Conversely, ratios of both D4 cortisol to cortisoltotal (0.05 ± 0.01; P < 0.05) and D4 cortisol to D3 cortisol (1.33 ± 0.11; P < 0.001) were lower in the hepatic vein than in the portal vein, indicating production of both cortisol and D3 cortisol by the liver. The viscera did not produce either cortisol (−8.1 ± 2.6 μg/min) or D3 cortisol (−0.2 ± 0.1 μg/min). In contrast, the liver produced both cortisol (22.7 ± 3.90 μg/min) and D3 cortisol (1.9 ± 0.4 μg/min) and accounted for all splanchnic cortisol and D3 cortisol production. Additionally, 11β-HSD-1 mRNA was approximately ninefold higher (P < 0.01) in liver than in visceral fat. Although 11β-HSD-2 gene expression was very low in visceral fat, the viscera released cortisone (P < 0.001) and D3 cortisone (P < 0.01) into the portal vein. CONCLUSIONS—The liver accounts for all splanchnic cortisol production in obese nondiabetic humans. In contrast, the viscera releases cortisone into the portal vein, thereby providing substrate for intrahepatic cortisol production.

[1]  Michael G. Sarr,et al.  Open and Laparoscopic Roux-en-Y Gastric Bypass: Our Techniques , 2007, Journal of Gastrointestinal Surgery.

[2]  R. Rizza,et al.  Splanchnic Cortisol Production in Dogs Occurs Primarily in the Liver , 2006, Diabetes.

[3]  B. Walker,et al.  The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. , 2005, Diabetes.

[4]  C. Cobelli,et al.  Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-beta hydroxysteroid dehydrogenase (11beta-hsd) type 1 pathway. , 2004, Diabetes.

[5]  B. Walker.  Is “Cushing’s disease of the omentum” an affliction of mouse and men? , 2004, Diabetologia.

[6]  J. Flier,et al.  Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. , 2003, The Journal of clinical investigation.

[7]  L. Abrahmsén,et al.  Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice , 2002, Diabetologia.

[8]  L. Abrahmsén,et al.  Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. , 2002, Journal of medicinal chemistry.

[9]  M. Alessi,et al.  Expression of the mRNA Coding for 11-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue from Obese Patients : An in Situ Hybridization Study , 2002 .

[10]  B. Walker,et al.  Distinguishing the activities of 11beta-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol. , 2002, The Journal of clinical endocrinology and metabolism.

[11]  J. Flier,et al.  A Transgenic Model of Visceral Obesity and the Metabolic Syndrome , 2001, Science.

[12]  P. Stewart,et al.  Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase. , 2001, Best practice & research. Clinical endocrinology & metabolism.

[13]  J. Seckl,et al.  Phenotypic analysis of mice bearing targeted deletions of 11β-hydroxysteroid dehydrogenases 1 and 2 genes , 2001, Molecular and Cellular Endocrinology.

[14]  M. Jensen,et al.  Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. , 2000, Diabetes.

[15]  G. Kaltsas,et al.  Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. , 1999, The Journal of clinical endocrinology and metabolism.

[16]  A J Howie,et al.  Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. , 1998, The Journal of clinical endocrinology and metabolism.

[17]  Edwards,et al.  11 b-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress , 1997 .

[18]  P. Stewart,et al.  Does central obesity reflect “Cushing's disease of the omentum”? , 1997, The Lancet.

[19]  C. Edwards,et al.  11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta- reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. , 1995, Endocrinology.